Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
3 "Cirrhosis"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Metabolic Risk/Epidemiology
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Hwi Seung Kim, Jiwoo Lee, Eun Hee Kim, Min Jung Lee, In Young Bae, Woo Je Lee, Joong-Yeol Park, Hong-Kyu Kim, Chang Hee Jung
Diabetes Metab J. 2023;47(1):104-117.   Published online January 26, 2023
DOI: https://doi.org/10.4093/dmj.2022.0081
  • 3,451 View
  • 180 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The association of myosteatosis measured using visual muscular quality map in computed tomography (CT) with nonalcoholic fatty liver disease (NAFLD), its severity, and fibrosis was analyzed in a large population.
Methods
Subjects (n=13,452) with abdominal CT between 2012 and 2013 were measured total abdominal muscle area (TAMA) at L3 level. TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA) and low attenuation muscle area (LAMA). The following variables were adopted as indicators of myosteatosis: SMA/body mass index (BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI. NAFLD and its severity were assessed by ultrasonography, and liver fibrosis was measured by calculating the NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB-4) scores.
Results
According to multiple logistic regression analyses, as quartiles of SMA/BMI, NAMA/BMI, and NAMA/TAMA increased, the odds ratios (ORs) for NAFLD decreased in each sex (P for trend <0.001 for all). The ORs of moderate/severe NAFLD were significantly higher in the Q1 group than in the Q4 group for SMA/BMI, NAMA/BMI, and NAMA/TAMA in men. The ORs of intermediate/high liver fibrosis scores assessed by NFS and FIB-4 scores increased linearly with decreasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA in each sex (P for trend <0.001 for all). Conversely, the risk for NAFLD and fibrosis were positively associated with LAMA/BMI quartiles in each sex (P for trend <0.001 for all).
Conclusion
A higher proportion of good quality muscle was associated with lower risks of NAFLD and fibrosis.

Citations

Citations to this article as recorded by  
  • Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
    Hwi Seung Kim, Hong-Kyu Kim, Chang Hee Jung
    Diabetes & Metabolism Journal.2023; 47(2): 304.     CrossRef
  • Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
    Eun Roh
    Diabetes & Metabolism Journal.2023; 47(2): 301.     CrossRef
  • Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?
    Giovanni Tarantino, Gaia Sinatti, Vincenzo Citro, Silvano Santini, Clara Balsano
    Internal and Emergency Medicine.2023; 18(7): 1887.     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Current view of the surgical anatomy of the anterolateral abdominal wall muscles and their aponeuroses
    A.V. Pavlov, A.S. Baranova, A.V. Fedoseyev, A.I. Vvedensky, G.S. Lazutina, N.V. Ovchinnikova, I.V. Bakharev
    Operativnaya khirurgiya i klinicheskaya anatomiya (Pirogovskii nauchnyi zhurnal).2023; 7(3): 44.     CrossRef
  • Muscle Fat Content Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Chinese Adults
    W. Guo, X. Zhao, D. Cheng, X. Liang, M. Miao, X. Li, J. Lu, N. Xu, Shuang Hu, Qun Zhang
    The Journal of nutrition, health and aging.2023; 27(11): 960.     CrossRef
Complications
Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Diabetes Metab J. 2022;46(1):104-116.   Published online July 13, 2021
DOI: https://doi.org/10.4093/dmj.2020.0273
  • 5,855 View
  • 193 Download
  • 4 Web of Science
  • 5 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Non-alcoholic steatohepatitis is closely associated with the progression of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). We investigated whether urinary N-acetyl-β-D-glucosaminidase (u-NAG), an early renal tubular damage biomarker in DKD, could be related to the degree of hepatic fibrosis in patients with T2DM.
Methods
A total of 300 patients with T2DM were enrolled in this study. Hepatic steatosis and fibrosis were determined using transient elastography. The levels of urinary biomarkers, including u-NAG, albumin, protein, and creatinine, and glucometabolic parameters were measured.
Results
Based on the median value of the u-NAG to creatinine ratio (u-NCR), subjects were divided into low and high u-NCR groups. The high u-NCR group showed a significantly longer duration of diabetes, worsened hyperglycemia, and a more enhanced hepatic fibrosis index. A higher u-NCR was associated with a greater odds ratio for the risk of higher hepatic fibrosis stage (F2: odds ratio, 1.99; 95% confidence interval [CI], 1.04 to 3.82). Also, u-NCR was an independent predictive marker for more advanced hepatic fibrosis, even after adjusting for several confounding factors (β=1.58, P<0.01).
Conclusion
The elevation of u-NAG was independently associated with a higher degree of hepatic fibrosis in patients with T2DM. Considering the common metabolic milieu of renal and hepatic fibrosis in T2DM, the potential use of u-NAG as an effective urinary biomarker reflecting hepatic fibrosis in T2DM needs to be validated in the future.

Citations

Citations to this article as recorded by  
  • Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial
    Xiao Tong Teong, Kai Liu, Andrew D. Vincent, Julien Bensalem, Bo Liu, Kathryn J. Hattersley, Lijun Zhao, Christine Feinle-Bisset, Timothy J. Sargeant, Gary A. Wittert, Amy T. Hutchison, Leonie K. Heilbronn
    Nature Medicine.2023; 29(4): 963.     CrossRef
  • Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
    Jaehyun Bae, Byung-Wan Lee
    Biomedicines.2023; 11(7): 1928.     CrossRef
  • Abdominal adipose tissue and type 2 diabetic kidney disease: adipose radiology assessment, impact, and mechanisms
    Fei Lu, Jinlei Fan, Fangxuan Li, Lijing Liu, Zhiyu Chen, Ziyu Tian, Liping Zuo, Dexin Yu
    Abdominal Radiology.2023; 49(2): 560.     CrossRef
  • β‐Amyrin ameliorates diabetic nephropathy in mice and regulates the miR‐181b‐5p/HMGB2 axis in high glucose‐stimulated HK‐2 cells
    Wenhua Xu, Hongwu Zhang, Qinfeng Zhang, Jialan Xu
    Environmental Toxicology.2022; 37(3): 637.     CrossRef
  • High Glycated Hemoglobin Instead of High Body Mass Index Might Increase the Urine N-Acetyl-β-D-glucosaminidase Con-Centration in Children and Adolescents with Diabetes Mellitus
    Jin-Soon Suh, Kyoung Soon Cho, Seul Ki Kim, Shin-Hee Kim, Won Kyoung Cho, Min Ho Jung, Moon Bae Ahn
    Life.2022; 12(6): 879.     CrossRef
Review
Others
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
Davide Povero, Ariel E. Feldstein
Diabetes Metab J. 2016;40(1):1-11.   Published online February 19, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.1.1
  • 5,982 View
  • 55 Download
  • 45 Web of Science
  • 46 Crossref
AbstractAbstract PDFPubReader   

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in adults and children worldwide. NAFLD has become a severe health issue and it can progress towards a more severe form of the disease, the non-alcoholic steatohepatitis (NASH). A combination of environmental factors, host genetics, and gut microbiota leads to excessive accumulation of lipids in the liver (steatosis), which may result in lipotoxicity and trigger hepatocyte cell death, liver inflammation, fibrosis, and pathological angiogenesis. NASH can further progress towards liver cirrhosis and cancer. Over the last few years, cell-derived extracellular vesicles (EVs) have been identified as effective cell-to-cell messengers that transfer several bioactive molecules in target cells, modulating the pathogenesis and progression of NASH. In this review, we focused on recently highlighted aspects of molecular pathogenesis of NASH, mediated by EVs via their bioactive components. The studies included in this review summarize the state of art regarding the role of EVs during the progression of NASH and bring novel insight about the potential use of EVs for diagnosis and therapeutic strategies for patients with this disease.

Citations

Citations to this article as recorded by  
  • Walnut fruit diaphragm ethanol extract ameliorates damage due to Triton WR‐1339‐induced hyperlipidemia in rats
    Esra Palabiyik, Ayse Nurseli Sulumer, Handan Uguz, Bahri Avci, Seda Askin, Hakan Askin
    European Journal of Lipid Science and Technology.2024;[Epub]     CrossRef
  • Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction
    Melina Belén Keingeski, Larisse Longo, Vitória Brum da Silva Nunes, Fabrício Figueiró, Danieli Rosane Dallemole, Adriana Raffin Pohlmann, Thalia Michele Vier Schmitz, Patrícia Luciana da Costa Lopez, Mário Reis Álvares-da-Silva, Carolina Uribe-Cruz
    Metabolic Syndrome and Related Disorders.2024;[Epub]     CrossRef
  • β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway
    Omayma AR Abo-Zaid, Fatma SM Moawed, Effet Soliman Ismail, Mostafa A. Farrag
    BMC Pharmacology and Toxicology.2023;[Epub]     CrossRef
  • Phospholipid metabolism in the liver – Implications for phosphatidylserine in non-alcoholic fatty liver disease
    Marziyeh Anari, Magdalene K. Montgomery
    Biochemical Pharmacology.2023; 213: 115621.     CrossRef
  • Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis
    Wenyan Zhang, Jing Zhang, Honglin Shi, Fang Liu, Haibin Yu, Hongbo Shi
    Hepatology International.2023; 17(5): 1170.     CrossRef
  • Role of extracellular vesicles in nonalcoholic fatty liver disease
    Wei Jiang, Youhui Xu, Jou-Chen Chen, Yi-Hung Lee, Yushin Hu, Chang-Hai Liu, Enqiang Chen, Hong Tang, Hua Zhang, Dongbo Wu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease
    Melania Manco, Nadia Panera, Annalisa Crudele, Maria Rita Braghini, Marzia Bianchi, Donatella Comparcola, Rita De Vito, Giuseppe Maggiore, Anna Alisi
    Pediatric Research.2022; 91(7): 1781.     CrossRef
  • The Neglected Role of Bile Duct Epithelial Cells in NASH
    Massimiliano Cadamuro, Alberto Lasagni, Samantha Sarcognato, Maria Guido, Roberto Fabris, Mario Strazzabosco, Alastair J. Strain, Paolo Simioni, Erica Villa, Luca Fabris
    Seminars in Liver Disease.2022; 42(01): 034.     CrossRef
  • Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Binjing Pan, Jing Cai, Pingping Zhao, Jingfang Liu, Songbo Fu, Gaojing Jing, Qianglong Niu, Qiong Li
    Osteoporosis International.2022; 33(11): 2275.     CrossRef
  • Ethanol Extract of Pinus koraiensis Leaves Mitigates High Fructose-Induced Hepatic Triglyceride Accumulation and Hypertriglyceridemia
    Min-Ho Lee, Sunyeong Park, Yinzhu Xu, Jung-Eun Kim, Hengmin Han, Jae-Hyeon Lee, Jean Kyung Paik, Hyo-Jeong Lee
    Applied Sciences.2022; 12(13): 6745.     CrossRef
  • TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis
    Yanmei Zhang, Xiaoxiao Ge, Yongqing Li, Bingyang Zhang, Peijun Wang, Mingju Hao, Peng Gao, Yueyi Zhao, Tao Sun, Sumei Lu, Wanshan Ma
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
    In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
    Scientific Reports.2021;[Epub]     CrossRef
  • Tabebuia rosea (Bertol.) DC. ethanol extract attenuates body weight gain by activation of molecular mediators associated with browning
    Elsa Cecilia Pagaza-Straffon, Carla Elena Mezo-González, David Armando Chavaro-Pérez, Jorge Cornejo-Garrido, Laurence A. Marchat, Claudia G. Benítez-Cardoza, Maricruz Anaya-Reyes, Cynthia Ordaz-Pichardo
    Journal of Functional Foods.2021; 86: 104740.     CrossRef
  • Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
    Zhangya He, Xiaomin Li, Hexiang Yang, Pei Wu, Shanshan Wang, Dan Cao, Xiaoxiao Guo, Zhangrui Xu, Jiayi Gao, Wanyu Zhang, Xiaoqin Luo
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Hepatic lipid droplet homeostasis and fatty liver disease
    Fabian Seebacher, Anja Zeigerer, Nora Kory, Natalie Krahmer
    Seminars in Cell & Developmental Biology.2020; 108: 72.     CrossRef
  • Orotic acid-treated hepatocellular carcinoma cells resist steatosis by modification of fatty acid metabolism
    Johanna Matilainen, Anne-Mari Mustonen, Kirsi Rilla, Reijo Käkelä, Sanna P. Sihvo, Petteri Nieminen
    Lipids in Health and Disease.2020;[Epub]     CrossRef
  • Liver fibrogenesis: un update on established and emerging basic concepts
    Erica Novo, Claudia Bocca, Beatrice Foglia, Francesca Protopapa, Marina Maggiora, Maurizio Parola, Stefania Cannito
    Archives of Biochemistry and Biophysics.2020; 689: 108445.     CrossRef
  • Relative contribution of fat diet and physical inactivity to the development of metabolic syndrome and non-alcoholic fat liver disease in Wistar rats
    Antonio Bovolini, Juliana Garcia, Maria Amparo Andrade, José Alberto Duarte
    Physiology & Behavior.2020; 225: 113040.     CrossRef
  • Novel hepatoprotective role of Leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK/SREBP1 signaling pathway
    Li Zhang, Hui-Xia Li, Wu-Si Pan, Farhan Ullah Khan, Cheng Qian, Feng-Rong Qi-Li, Xiaojun Xu
    Biomedicine & Pharmacotherapy.2019; 110: 571.     CrossRef
  • Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study
    You‐Cheol Hwang, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2019; 27(8): 1360.     CrossRef
  • Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer
    Hongbo Wang, Zaiming Lu, Xiangxuan Zhao
    Journal of Hematology & Oncology.2019;[Epub]     CrossRef
  • Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease
    Elena N. Shirokova, Chavdar S. Pavlov, Anna D. Karaseva, Aliya M. Alieva, Alla V. Sedova, Vladimir T. Ivashkin
    Annals of the Russian academy of medical sciences.2019; 74(1): 5.     CrossRef
  • Curcumin Recovers Intracellular Lipid Droplet Formation Through Increasing Perilipin 5 Gene Expression in Activated Hepatic Stellate Cells In Vitro
    Xiao-qun Han, San-qing Xu, Jian-guo Lin
    Current Medical Science.2019; 39(5): 766.     CrossRef
  • Lipid mediators of liver injury in nonalcoholic fatty liver disease
    Suthat Liangpunsakul, Naga Chalasani
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2019; 316(1): G75.     CrossRef
  • Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
    Maurizio Parola, Massimo Pinzani
    Molecular Aspects of Medicine.2019; 65: 37.     CrossRef
  • Ostreolysin induces browning of adipocytes and ameliorates hepatic steatosis
    Lili Nimri, Katerina Staikin, Irena Peri, Einav Yehuda‐Shnaidman, Betty Schwartz
    Journal of Gastroenterology and Hepatology.2018; 33(12): 1990.     CrossRef
  • miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Chang-Hai Liu, Javier Ampuero, Antonio Gil-Gómez, Rocío Montero-Vallejo, Ángela Rojas, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Manuel Romero-Gómez
    Journal of Hepatology.2018; 69(6): 1335.     CrossRef
  • Efficient scalable production of therapeutic microvesicles derived from human mesenchymal stem cells
    Jae Min Cha, Eun Kyoung Shin, Ji Hee Sung, Gyeong Joon Moon, Eun Hee Kim, Yeon Hee Cho, Hyung Dal Park, Hojae Bae, Jinseok Kim, Oh Young Bang
    Scientific Reports.2018;[Epub]     CrossRef
  • Changes in the Structure of the Liver during Obesity (Literature Review)
    V. I. Prymachenko
    Ukraïnsʹkij žurnal medicini, bìologìï ta sportu.2018; 4(2): 45.     CrossRef
  • Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
    Juan Pablo Arab, Marco Arrese, Michael Trauner
    Annual Review of Pathology: Mechanisms of Disease.2018; 13(1): 321.     CrossRef
  • Apoptosis and non-alcoholic fatty liver diseases
    Tatsuo Kanda, Shunichi Matsuoka, Motomi Yamazaki, Toshikatsu Shibata, Kazushige Nirei, Hiroshi Takahashi, Tomohiro Kaneko, Mariko Fujisawa, Teruhisa Higuchi, Hitomi Nakamura, Naoki Matsumoto, Hiroaki Yamagami, Masahiro Ogawa, Hiroo Imazu, Kazumichi Kuroda
    World Journal of Gastroenterology.2018; 24(25): 2661.     CrossRef
  • Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH
    Y Ilan, K Shailubhai, A Sanyal
    Clinical and Experimental Immunology.2018; 193(3): 275.     CrossRef
  • Long-term exposure to high-sucrose diet down-regulates hepatic endoplasmic reticulum-stress adaptive pathways and potentiates de novo lipogenesis in weaned male mice
    Karla Frida Torres Flister, Bruno Araújo Serra Pinto, Lucas Martins França, Caio Fernando Ferreira Coêlho, Pâmela Costa dos Santos, Caroline Castro Vale, Daniela Kajihara, Victor Debbas, Francisco Rafael Martins Laurindo, Antonio Marcus de Andrade Paes
    The Journal of Nutritional Biochemistry.2018; 62: 155.     CrossRef
  • Blood-Based Novel Biomarkers for Nonalcoholic Steatohepatitis
    Yun Qiu, Sufan Wang, Ting Wan, Mingtong Ye, Rui Jiang, Lei Pei, Lili Yang
    Biomarkers in Medicine.2018; 12(5): 501.     CrossRef
  • The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
    Bojan Jorgačević, Danijela Vučević, Ivana Đuričić, Slađana Šobajić, Dušan Mladenović, Milena Vesković, Rada Ješić Vukićević, Tatjana Radosavljević
    Chemistry and Physics of Lipids.2017; 204: 85.     CrossRef
  • Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition
    Soo Hyun Kim, Gyuri Kim, Dai Hoon Han, Milim Lee, Irene Kim, Bohkyung Kim, Kook Hwan Kim, Young-Mi Song, Jeong Eun Yoo, Hye Jin Wang, Soo Han Bae, Yong-Ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Myung-Shik Lee
    Autophagy.2017; 13(10): 1767.     CrossRef
  • Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Seung Hwan Han, Kwang-Hyub Han, Bong-Soo Cha, Choon Hee Chung, Byung-Wan Lee
    Metabolism.2017; 66: 23.     CrossRef
  • Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease
    Gyuri Kim, Kwang Joon Kim, Yumie Rhee, Sung-Kil Lim, Salvatore Petta
    PLOS ONE.2017; 12(7): e0182202.     CrossRef
  • Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation
    Jihyun Kim, Da Young Lee, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee, Susanne Kaser
    PLOS ONE.2017; 12(7): e0180118.     CrossRef
  • Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats
    Xu-Jia Chen, Wen-Jing Liu, Meng-Liang Wen, Hong Liang, Shao-Mei Wu, Yun-Zhen Zhu, Jiang-Yuan Zhao, Xiang-Qian Dong, Ming-Gang Li, Li Bian, Cheng-Gang Zou, Lan-Qing Ma
    Scientific Reports.2017;[Epub]     CrossRef
  • Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH
    Melanie Tran, Sang-Min Lee, Dong-Ju Shin, Li Wang
    JCI Insight.2017;[Epub]     CrossRef
  • Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis
    Nada Pejnovic, Ilija Jeftic, Nemanja Jovicic, Nebojsa Arsenijevic, Miodrag L Lukic
    World Journal of Gastroenterology.2016; 22(44): 9706.     CrossRef
  • Hepatocyte mitochondrial DNA released in microparticles and toll‐like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis
    Maria Eugenia Inzaugarat, Alexander Wree, Ariel E. Feldstein
    Hepatology.2016; 64(2): 669.     CrossRef
  • Metabolic aspects of adult patients with nonalcoholic fatty liver disease
    Ludovico Abenavoli, Natasa Milic, Laura Di Renzo, Tomislav Preveden, Milica Medić-Stojanoska, Antonino De Lorenzo
    World Journal of Gastroenterology.2016; 22(31): 7006.     CrossRef
  • Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions
    Maria Grazia Clemente, Claudia Mandato, Marco Poeta, Pietro Vajro
    World Journal of Gastroenterology.2016; 22(36): 8078.     CrossRef
  • Gut Microbiota and Metabolic Health: The Potential Beneficial Effects of a Medium Chain Triglyceride Diet in Obese Individuals
    Sabri Rial, Antony Karelis, Karl-F. Bergeron, Catherine Mounier
    Nutrients.2016; 8(5): 281.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal